Mark A. Eckardt
Impact in
- Biotechnology top 5%
- Cancer Research and Treatments
-
- Sarcoma Diagnosis and Treatment
- Advanced Breast Cancer Therapies
Papers in
-
- Sarcoma Diagnosis and Treatment 9
-
- Cancer Research and Treatments 9
- Co-authors
- Fritz C. Eilber (19 shared papers)Arun S. Singh (18 shared papers)Scott D. Nelson (15 shared papers)Remi M. Ajiboye (3 shared papers)Jason T. Hamamoto (3 shared papers)Jeffrey C. Wang (3 shared papers)Nicholas M. Bernthal (7 shared papers)Sarah Dry (16 shared papers)
- Journals
- Journal of Cellular Biochemistry (4 papers)Oncotarget (2 papers)Journal of Pediatric Hematology/Oncology (2 papers)Journal of Nuclear Medicine (1 paper)Biochemical and Biophysical Research Communications (1 paper)
- Partner nations
- United StatesJapanThailand
In The Last Decade
Mark A. Eckardt
29 papers receiving 533 citations
Peers
Comparison fields: 5 of 50
- Biotechnology 161
- Pulmonary and Respiratory Medicine 164
- Oncology 111
- Rheumatology 60
- Oral Surgery 23
Countries citing papers authored by Mark A. Eckardt
This map shows the geographic impact of Mark A. Eckardt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark A. Eckardt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark A. Eckardt more than expected).
Fields of papers citing papers by Mark A. Eckardt
This network shows the impact of papers produced by Mark A. Eckardt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark A. Eckardt. The network helps show where Mark A. Eckardt may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark A. Eckardt, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 32 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity. | 2013 | 90 |
| 2 | 2017 | 52 | |
| 3 | 2015 | 40 | |
| 4 | 2011 | 36 | |
| 5 | 2018 | 31 | |
| 6 | 2018 | 29 | |
| 7 | 2016 | 29 | |
| 8 | 2013 | 22 | |
| 9 | 2013 | 22 | |
| 10 | 2017 | 22 | |
| 11 | 2016 | 18 | |
| 12 | 2018 | 16 | |
| 13 | 2013 | 16 | |
| 14 | 2019 | 14 | |
| 15 | 2017 | 13 | |
| 16 | 2019 | 12 | |
| 17 | 2018 | 10 | |
| 18 | 2018 | 9 | |
| 19 | 2021 | 8 | |
| 20 | 2017 | 8 |
About Mark A. Eckardt
Mark A. Eckardt is a scholar working on Pulmonary and Respiratory Medicine, Biotechnology, Biomedical Engineering, Oncology and Genetics, having authored 32 papers that have together received 536 indexed citations. Recurring topics across this work include Sarcoma Diagnosis and Treatment (9 papers), Cancer Research and Treatments (9 papers), Nanoplatforms for cancer theranostics (8 papers), Virus-based gene therapy research (7 papers), Spine and Intervertebral Disc Pathology (3 papers), Neurofibromatosis and Schwannoma Cases (2 papers), Bone Tumor Diagnosis and Treatments (2 papers) and Hematological disorders and diagnostics (2 papers). The work is most often cited by research in Biotechnology (161 citations), Pulmonary and Respiratory Medicine (164 citations), Oncology (111 citations), Rheumatology (60 citations) and Oral Surgery (23 citations). Mark A. Eckardt has collaborated with scholars based in United States, Japan and Thailand. Frequent co-authors include Fritz C. Eilber, Arun S. Singh, Scott D. Nelson, Remi M. Ajiboye, Jason T. Hamamoto, Jeffrey C. Wang, Nicholas M. Bernthal, Sarah Dry, Jeffrey J. Eċkardt and Kei Kawaguchi. Their work appears in journals such as Journal of Cellular Biochemistry, Oncotarget, Journal of Pediatric Hematology/Oncology, Journal of Nuclear Medicine and Biochemical and Biophysical Research Communications.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.